Next Article in Journal
The Flavonoid Metabolite 2,4,6-Trihydroxybenzoic Acid Is a CDK Inhibitor and an Anti-Proliferative Agent: A Potential Role in Cancer Prevention
Next Article in Special Issue
The Role of SVZ Stem Cells in Glioblastoma
Previous Article in Journal
Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
Previous Article in Special Issue
Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma
Open AccessPerspective

The ‘Ins and Outs’ of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong?

1
Department of Neurosurgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK
2
Department of Oncology & Metabolism, The University of Sheffield Medical School, Sheffield S10 2RX, UK
3
NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(3), 426; https://doi.org/10.3390/cancers11030426
Received: 26 February 2019 / Revised: 21 March 2019 / Accepted: 23 March 2019 / Published: 25 March 2019
(This article belongs to the Special Issue Glioblastoma: State of the Art and Future Perspectives)
In this perspective, we congratulate the international efforts to highlight critical challenges in brain tumor research through a recent Consensus Statement. We also illustrate the importance of developing more accurate and clinically relevant early translational in vitro brain tumor models—a perspective given limited emphasis in the Consensus Statement, despite in vitro models being widely used to prioritize candidate therapeutic strategies prior to in vivo studies and subsequent clinical trials. We argue that successful translation of effective novel treatments into the clinic will require investment into the development of more predictive early pre-clinical models. It is in the interest of researchers, clinicians, and ultimately, patients that the most promising therapeutic candidates are identified and translated toward use in the clinic. Highlighting the value of early pre-clinical brain tumor models and debating how such models can be improved is of the utmost importance to the neuro-oncology research community and cancer research more broadly. View Full-Text
Keywords: pre-clinical; research models; 3D models; brain tumors; cancer stem cells; glioblastoma; DNA damage response (DDR) pre-clinical; research models; 3D models; brain tumors; cancer stem cells; glioblastoma; DNA damage response (DDR)
MDPI and ACS Style

Rominiyi, O.; Al-Tamimi, Y.; Collis, S.J. The ‘Ins and Outs’ of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong? Cancers 2019, 11, 426.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop